Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer

N. A. Avxentyev; M. Yu. Frolov; Yu. V. Makarova

Cancer Urology
Onkourologiâ

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

User

eng | рус

Cancer Urology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Avxentyev N.A., Frolov M.Yu., Makarova Yu.V. Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Cancer Urology. 2019;15(2):86-99. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-2-86-99

Views PDF (Rus): 510

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Boris Ya. Alekseev

About the Authors

N. A. Avxentyev
Research Institute of Finance; Institute of Social Analysis and Prognosis, Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Build 2, 3 Nastas’inskiy Pereulok, Moscow 127006,

Build. 1, 82 Vernadskogo Prospekt, Moscow 119571

M. Yu. Frolov
Volgograd State Medical University, Ministry of Health of Russia; Volgograd Medical Scientific Center
Russian Federation

1 Pavshikh Bortsov Ploshchad’, Volgograd 400131,

1 Pavshikh Bortsov Ploshchad’, Volgograd 400131

Yu. V. Makarova
Research Institute of Finance
Russian Federation

Build 2, 3 Nastas’inskiy Pereulok, Moscow 127006

Notifications

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

For citations:

Cookies policy